ARVN Overview
Upcoming Projects (ARVN)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (ARVN)
-
Looking into the ARDENT clinical trial data on Arvinas' PROTAC Degrader Bavdegalutamide (ARV-110) in prostate cancer
Ticker: ARVN
Executed On: Sep 22, 2023 at 01:00 PM EDT -
Examining the potential of Arvinas' Novel PROTAC Degrader Bavdegalutamide (ARV-110) in prostate cancer after New Data from Completed Phase 1 Dose Escalation
Ticker: ARVN
Executed On: Feb 21, 2023 at 11:00 AM EST -
Discussing the recent data presented on Arvinas ARV-471; a novel, potent, orally bioavailable PROTAC protein degrader that selectively targets the ER in BREAST CANCER
Ticker: ARVN
Executed On: Feb 07, 2023 at 04:30 PM EST -
Discussing protein degraders in the oncology space
Tickers: ARVN, CCCC, NRIX, KYMR
Executed On: Jan 05, 2022 at 02:00 PM EST
Upcoming & Overdue Catalysts (ARVN)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (ARVN)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
